| Document |
Document Title |
|
WO/2023/138601A1 |
The present invention discloses a bridged ring-substituted heteroaryl-pyran derivative and a use thereof, and in particular discloses a compound as represented in formula (VI) or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/139992A1 |
The present invention addresses the problem of improving the characteristics of a photoelectric conversion device. The present invention pertains to an ink composition containing: a semiconductor material including at least one p-type ...
|
|
WO/2023/141536A1 |
The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SL...
|
|
WO/2023/141225A1 |
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazo...
|
|
WO/2023/138662A1 |
Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.
|
|
WO/2023/140374A1 |
A compound of the general formula has excellent light-emitting properties. A represents a 2- or 4-cyanophenyl group or a cyanopyridyl group; one of R2 and R3 represents an acceptor group; the other of R2 and R3 and at least one of R1, R4...
|
|
WO/2023/138254A1 |
The present invention relates to a heterocyclic compound, an organic electroluminescent material, and an organic electroluminescent element. The structure of the heterocyclic compound is as shown in formula (I). The heterocyclic compound...
|
|
WO/2023/138317A1 |
Disclosed are a compound having RIPK1 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound is as shown in general formula I, and the definition of each substituent is as described in the d...
|
|
WO/2023/138524A1 |
Disclosed are a compound having an X-Y-Z structure, and a tautomer, a deuterated compound or a pharmaceutical salt thereof. X is a KRAS protein binding ligand compound, Z is an E3 ligase binding ligand compound, and Y is a linking chain ...
|
|
WO/2023/134711A1 |
Disclosed are a cyclopiperidine compound, a preparation method therefor, and a use thereof. The cyclopiperidine compound of the present invention is represented by formula I'. The cyclopiperidine compound of the present invention has a b...
|
|
WO/2023/137356A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/137223A1 |
The disclosure includes compounds of Formula (3) wherein each of Warhead, R1, R2, R3, L1, L2, L3, L4, L5, L6, R0, Q1, Q2, Q3, W1, W2, m, n, and i, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmu...
|
|
WO/2023/134465A1 |
Disclosed in the present invention are a nitrogen-containing heterocyclic compound, and a preparation method therefor, an intermediate thereof and the use thereof. Provided in the present invention is a nitrogen-containing heterocyclic c...
|
|
WO/2023/134266A1 |
A 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a s...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/131167A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a...
|
|
WO/2023/133543A1 |
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
|
|
WO/2023/125627A1 |
Relates a nitrogen-containing heterocyclic compound and an application thereof. Relates a nitrogen-containing heterocyclic compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof or a solvate thereof. The ...
|
|
WO/2023/126297A1 |
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...
|
|
WO/2023/125845A1 |
Provided are an anti-RSV compound as shown in formula (I), and a method for preparation thereof and an application thereof. The compound shown in the formula (I) has very high inhibitory activity on RSV, has excellent efficacy, in-vitro/...
|
|
WO/2023/125907A1 |
Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation...
|
|
WO/2023/125989A1 |
A quinazoline compound and an application thereof. The quinazoline compound is shown as a formula 1, it has a good inhibiting effect on KRAS G12D mutant protein and has a good patent medicine prospect.
|
|
WO/2023/116748A1 |
Provided are a compound as represented by formula (I) and a pharmaceutical composition thereof. The compound or the pharmaceutical composition can regulate the activity of JAK, especially the activity of TYK2, and can be used for prevent...
|
|
WO/2023/116724A1 |
The present disclosure relates to the field of medicine, and specifically to the use of a new-type securinine dimer or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating Alzheimer's disease. The new-type...
|
|
WO/2023/116594A1 |
A substituted fused heterocyclic compound, and a preparation method therefor and the use thereof. Provided is a compound having the structure of formula (I) or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutica...
|
|
WO/2023/116763A1 |
Provided are a pyridazine compound, and a pharmaceutical composition and the use thereof. Specifically, the compound has a structure as shown in formula (I), can interfere with the interaction between an SOS1 protein and an RAS protein, ...
|
|
WO/2023/115142A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
|
|
WO/2023/118250A1 |
The present invention relates to small molecules capable of inhibiting SOS1 (Son of Sevenless) and their salts. Specifically, the present invention relates to heterocyclic compounds of general formula (I) or salts thereof wherein A, X, R...
|
|
WO/2023/122140A1 |
The present disclosure provides compounds, compositions, and methods useful for inhibiting PARP1, and/or treating a disease, disorder, or condition associated with PARP1, and/or treating cancer.
|
|
WO/2023/116934A1 |
The present invention relates to a KRASG12D protein hydrolysis regulator, and a preparation method therefor and the use thereof. Specifically, a compound of the present invention has the structure as shown in formula (I). The present inv...
|
|
WO/2023/114119A1 |
Provided herein are methods of preparing crystalline, selpercatinib Form A, which contains little to none of the thermodynamically more stable, crystalline selpercatinib Form B. Selpercatinib is useful in the treatment and prevention of ...
|
|
WO/2023/110958A1 |
The invention provides new MAGL inhibitors having the general formula (II)AB(II)wherein the variables are as described herein, compositions including the compounds,processes of manufacturing the compounds and methods of using the compounds.
|
|
WO/2023/109883A1 |
Disclosed are a class of compounds having a new structure as an ATR inhibitor, and a stereoisomer, an optical isomer, a pharmaceutical salt, a prodrug and a solvate thereof. An in-vitro enzyme inhibitory activity study shows that the com...
|
|
WO/2023/114733A1 |
Provided herein are KRAS modulating compounds, such as compounds of Formula (I) and various Sub Formulas or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modul...
|
|
WO/2023/109929A1 |
Provided are a class of compounds, a stereoisomer, an optical isomer, a pharmaceutically acceptable salt, a prodrug, a solvate (for example, a hydrate) or an isotope derivative thereof. The compounds have a tri-heterocyclic structure (fo...
|
|
WO/2023/109959A1 |
The present invention relates to the field of medicines, specifically relates to a CDK9 inhibitor compound represented by formula (I), and a pharmaceutically acceptable salt or isomer thereof, and also relates to a pharmaceutical composi...
|
|
WO/2023/114539A1 |
The present invention provides novel amino chromen-2-one compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunct...
|
|
WO/2023/107714A2 |
This disclosure provides compounds and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, di...
|
|
WO/2023/105491A1 |
The present invention relates to novel compounds described herein, the method of preparing the same, its pharmaceutical composition and method for use thereof. In particular the invention to compounds of formula A or their pharmaceutical...
|
|
WO/2023/104018A1 |
Provided in the present invention is a substituted bicyclic heteroaryl compound as a KRAS G12D inhibitor. Also provided in the present invention are a pharmaceutical composition containing the compound, and the use thereof in the treatme...
|
|
WO/2023/102184A1 |
The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 12 (CDK12), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/098426A1 |
Disclosed are 7-(naphthalene-l-yl)pyrido[4,3-d]pyrimidine derivatives, a preparation method therefor, and the use thereof. In particular relating to KRas G12D inhibitors having the structure of formula (I), a preparation method therefor,...
|
|
WO/2023/098730A1 |
The present disclosure relates to a compound containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I", a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor...
|
|
WO/2023/100942A1 |
[Problem] To develop an artificial catalyst capable of inhibiting aggregation of pathogenic amyloids (tau amyloids) formed by the aggregation of tau proteins, and to provide a prophylactic and therapeutic medicine for amyloid-related dis...
|
|
WO/2023/100844A1 |
The present invention addresses the problem of reducing a dark current. The present invention relates to a compound represented by formula (I). (I): A1―P―A2 (In formula (I), each of A1 and A2 is independently an electron-withdrawin...
|
|
WO/2023/098880A1 |
A fused ring derivative having a structure shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing a compound, and a use of the pharmaceutical composition as a regulator in treating cancer-rel...
|
|
WO/2023/039240A9 |
Disclosed herein are heterocyclic compounds that inhibit the binding of KRas. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the KRas inhibitors are disclosed, alone or in combination with oth...
|
|
WO/2023/093718A1 |
Provided are a crystal form of a compound of formula (I), a method for preparing the crystal form, a pharmaceutical composition containing the crystal form, and the use thereof in the preparation of a drug for treating diseases, disorder...
|
|
WO/2023/093094A1 |
The present application provides an organic electroluminescent device and a display apparatus. The organic electroluminescent device comprises a light-emitting layer, which comprises a triplet-triplet annihilation-type host and a fluores...
|
